Recently, Trop-2 is also being tested as a druggable target, since an anti-Trop-2 antibody-drug conjugate is being used to treat patients with several metastatic neoplasms, including triple-negative breast cancer and non-small-cell and small-cell lung cancer [20]. Here, TACSTD2 is linked to metastatic neoplasm.